A scoping review of imatinib-induced testicular toxicity and male fertility impairment
Open Access
- 14 May 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17
Abstract
Background: Imatinib, the first-generation tyrosine kinase inhibitor (TKI), has been widely adopted as frontline therapy for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Growing evidence indicates potential gonadotoxic effects, raising concerns about its long-term impact on male fertility. Objective: This scoping review was undertaken to synthesize preclinical and clinical evidence on imatinib-induced reproductive toxicity in males, with emphasis on mechanisms, dose- and age-dependent susceptibility, and reversibility of testicular injury. Methods: A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science following PRISMA-ScR guidelines. Twenty studies published between 2003 and 2025 were included. Results: Across animal and human studies, inhibition of Proto-oncogene c-KIT (c-KIT) and Platelet-Derived Growth Factor Receptor (PDGFR) signaling was consistently observed, leading to germ cell apoptosis, impaired spermatogonial proliferation, and disruption of the blood–testis barrier (BTB). Dose-dependent reductions in testosterone and sperm density were documented, with partial recovery after drug discontinuation in several models. However, neonatal exposure was more often associated with persistent or irreversible testicular damage. Conclusion: Imatinib exerts gonadotoxic effects through inhibition of c-KIT/PDGFR signaling, disruption of the BTB, and dysregulation of the hypothalamic–pituitary–gonadal axis in a dose- and age-dependent manner. Although partial recovery is possible after withdrawal, neonatal and prepubertal exposures carry a high risk of irreversible impairment. These findings highlight the need for systematic fertility counseling and preservation in adolescent and reproductive-age males, in line with the 2025 European LeukemiaNet (ELN) recommendations.Keywords
This publication has 70 references indexed in Scilit:
- The Role of SIRT1 in LeukemiaCurrent Treatment Options in Oncology, 2024
- New Insights of Target Therapy: Effects of Tyrosine Kinase Inhibitors on Male Gonadal Function: A Systematic ReviewClinical Genitourinary Cancer, 2024
- Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoringAmerican Journal of Hematology, 2022
- Imatinib reduces the fertility of male mice by penetrating the blood-testis barrier and inducing spermatogonia apoptosisReproductive Biology, 2021
- Chronic lymphocytic leukaemia and Richter's transformation: multimodal review and new imaging paradigmsClinical Radiology, 2021
- Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working GroupPediatric Blood & Cancer, 2019
- Impact of Imatinib on the Fertility of Male Patients with Chronic Myelogenous Leukaemia in the Chronic PhaseTargeted Oncology, 2017
- Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phasePediatric Blood & Cancer, 2013
- Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse modelLeukemia Research, 2012
- Preclinical Evaluation of Juvenile Toxicity2010